The Global FH registry publication in the Lancet
Updated Dec 8th 2021
Global FHSC registry highlights the challenges of familial hypercholesterolaemia: late detection, undertreatment, and disparities between men and women.
First data from the European Atherosclerosis Society (EAS) Familial Hypercholesterolaemia Studies
Collaboration (FHSC) global registry of over 42,000 individuals from 56 countries, provides a unique snapshot into the worldwide burden and challenges of FH care. Detection needs to be earlier, with greater use of intensive lipid-lowering therapy, including combination treatment, to attain guideline goals. Treatment of women also lags that of men. The findings were published on September 8th, 2021, in The Lancet.
FH Europe welcomes this important paper from the FHSC. Together with this global FH registry, we strive to improve healthcare policy around familial hypercholesterolaemia, so that individuals and their families impacted by inherited high cholesterol are identified as early as possible and treated optimally. These data will drive innovation and support our advocacy efforts to prevent premature cardiovascular disease and to offer all FH patients an equal opportunity to live longer and healthier lives.
While the original publication in The Lancet 2021 can be found here, we are pleased to share with you a lay summary of this first major publication to come from the FH Studies Collaboration prepared in collaboration with EAS FHSC here. You can also watch a video with Prof Kausik Ray, EAS President and FHSC Lead, where he introduces the paper and explains the significance of its findings for patients and public health policy.
The official press release can be found here
FH Europe is supported by an educational grant from Amgen Limited, Sanofi, Regeneron, Akcea Therapeutics Inc. and Amryt